Microsatellite unstable (MSI) colorectal cancers (CRCs) are due to DNA mismatch repair
(MMR) deficiency and occurs in15% of non-metastatic diseases and 5% in the metastatic …

In the era of targeted therapy based on genomic alterations, the treatment strategy for
metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment …

Background PD-1 blockade is highly effective in patients with mismatch repair-deficient or
microsatellite instability-high metastatic colorectal cancer. The role of single-agent PD-1 …

Colorectal cancer (CRC) with deficient DNA mismatch repair (dMMR) is characterized by
hypermutation leading to abundant neoantigens that activate an antitumor immune …

Background Mismatch repair–deficient (dMMR) tumors can be found in 10 to 15% of patients
with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited …

PURPOSE Early-onset (EO) colorectal cancer (CRC, age< 50 years) incidence is
increasing. Decisions on optimal adjuvant therapy should consider treatment adherence …

Immune checkpoint inhibitors (ICIs) are shown to be effective among patients with metastatic
colorectal cancer (mCRC) harboring high microsatellite instability (MSI-H) and/or mismatch …

Simple Summary A subset of colorectal cancers (CRCs) displays deficient DNA mismatch
repair (dMMR) that leads to microsatellite instability (MSI). These tumors have distinct …

PURPOSE We conducted a systematic review to evaluate the outcome of patients with early-
stage (stages I-III) mismatch repair deficient (dMMR) colorectal cancer (CRC) receiving …

Approximately 4-5% of patients with metastatic colorectal cancer (mCRC) have mismatch
repair deficient (dMMR)/microsatellite instability-high (MSI-H) tumours. These tumours …